192 related articles for article (PubMed ID: 35007144)
1. Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease.
Bleakley M; Sehgal A; Seropian S; Biernacki MA; Krakow EF; Dahlberg A; Persinger H; Hilzinger B; Martin PJ; Carpenter PA; Flowers ME; Voutsinas J; Gooley TA; Loeb K; Wood BL; Heimfeld S; Riddell SR; Shlomchik WD
J Clin Oncol; 2022 Apr; 40(11):1174-1185. PubMed ID: 35007144
[TBL] [Abstract][Full Text] [Related]
2. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.
Bleakley M; Heimfeld S; Loeb KR; Jones LA; Chaney C; Seropian S; Gooley TA; Sommermeyer F; Riddell SR; Shlomchik WD
J Clin Invest; 2015 Jul; 125(7):2677-89. PubMed ID: 26053664
[TBL] [Abstract][Full Text] [Related]
4. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3
Lum SH; James B; Ottaviano G; Ewins AM; Patrick K; Ali S; Carpenter B; Silva J; Tewari S; Furness C; Thomas A; Shenton G; Bonney D; Moppett J; Hambleton S; Gennery AR; Amrolia P; Gibson B; Hough R; Rao K; Slatter M; Wynn R
Transplant Cell Ther; 2024 Mar; 30(3):314.e1-314.e12. PubMed ID: 38103787
[TBL] [Abstract][Full Text] [Related]
6. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
[TBL] [Abstract][Full Text] [Related]
7. Triple-Drug Graft-versus-Host Disease Prophylaxis after HLA-Matched Unrelated Donor Nonmyeloablative Allogenic Hematopoietic Stem Cell Transplantation.
Wegener A; Andersen NS; Friis LS; Petersen SL; Schjødt I; Kornblit B; Sengeløv H; Gjærde LK
Transplant Cell Ther; 2023 Sep; 29(9):575.e1-575.e6. PubMed ID: 37301257
[TBL] [Abstract][Full Text] [Related]
8. Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors.
Lazaryan A; Weisdorf DJ; DeFor T; Brunstein CG; MacMillan ML; Bejanyan N; Holtan S; Blazar BR; Wagner JE; Arora M
Biol Blood Marrow Transplant; 2016 Jan; 22(1):134-40. PubMed ID: 26365153
[TBL] [Abstract][Full Text] [Related]
9. Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation.
Saad A; Lamb L; Wang T; Hemmer MT; Spellman S; Couriel D; Alousi A; Pidala J; Abdel-Azim H; Agrawal V; Aljurf M; Beitinjaneh AM; Bhatt VR; Buchbinder D; Byrne M; Cahn JY; Cairo M; Castillo P; Chhabra S; Diaz MA; Farhan S; Floisand Y; Frangoul HA; Gadalla SM; Gajewski J; Gale RP; Gandhi M; Gergis U; Hamilton BK; Hematti P; Hildebrandt GC; Kamble RT; Kanate AS; Khandelwal P; Lazaryan A; MacMillan M; Marks DI; Martino R; Mehta PA; Nishihori T; Olsson RF; Patel SS; Qayed M; Rangarajan HG; Reshef R; Ringden O; Savani BN; Schouten HC; Schultz KR; Seo S; Shaffer BC; Solh M; Teshima T; Urbano-Ispizua A; Verdonck LF; Vij R; Waller EK; William B; Wirk B; Yared JA; Yu LC; Arora M; Hashmi S
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1875-1883. PubMed ID: 31085303
[TBL] [Abstract][Full Text] [Related]
10. High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation.
Pedraza A; Jorge S; Suárez-Lledó M; Pereira A; Gutiérrez-García G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
Transplant Cell Ther; 2021 Jul; 27(7):619.e1-619.e8. PubMed ID: 33895157
[TBL] [Abstract][Full Text] [Related]
11. Ex Vivo CD34
Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O'Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM
Biol Blood Marrow Transplant; 2017 Mar; 23(3):452-458. PubMed ID: 28017734
[TBL] [Abstract][Full Text] [Related]
12. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
13. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis.
Srinivasan A; Raffa E; Wall DA; Schechter T; Ali M; Chopra Y; Kung R; Chiang KY; Krueger J
Transplant Cell Ther; 2022 Mar; 28(3):158.e1-158.e9. PubMed ID: 34838785
[TBL] [Abstract][Full Text] [Related]
14. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
15. Incidence, Risk Factors, Characteristics, and Outcome of Chronic Graft Versus Host Disease in Children Undergoing Haploidentical Peripheral Blood Stem Cell Transplant With Post-transplant Cyclophosphamide.
Arora S; Thakkar D; Upasana K; Yadav A; Rastogi N; Sharma PS; Yadav SP
J Pediatr Hematol Oncol; 2024 Jan; 46(1):e44-e50. PubMed ID: 37983773
[TBL] [Abstract][Full Text] [Related]
16. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
[TBL] [Abstract][Full Text] [Related]
17. Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.
Moiseev IS; Pirogova OV; Alyanski AL; Babenko EV; Gindina TL; Darskaya EI; Slesarchuk OA; Bondarenko SN; Afanasyev BV
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1037-1042. PubMed ID: 26970381
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.
Ceberio I; Devlin SM; Sauter C; Barker JN; Castro-Malaspina H; Giralt S; Ponce DM; Lechner L; Maloy MA; Goldberg JD; Perales MA
Leuk Lymphoma; 2015 Mar; 56(3):663-70. PubMed ID: 24913499
[TBL] [Abstract][Full Text] [Related]
19. [The impact of donor-to-recipient gender compatibility on outcomes of haploid hematopoietic stem cell transplantation in patients with hematological malignancies].
Hu SS; Wu YB; Zhu PP; Shi JM; Yu J; Zhao YM; Lai XY; Liu LZ; Fu HR; Huang H; Luo Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):992-1002. PubMed ID: 36709104
[No Abstract] [Full Text] [Related]
20. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.
Bonifazi F; Solano C; Wolschke C; Sessa M; Patriarca F; Zallio F; Nagler A; Selleri C; Risitano AM; Messina G; Bethge W; Herrera P; Sureda A; Carella AM; Cimminiello M; Guidi S; Finke J; Sorasio R; Ferra C; Sierra J; Russo D; Benedetti E; Milone G; Benedetti F; Heinzelmann M; Pastore D; Jurado M; Terruzzi E; Narni F; Völp A; Ayuk F; Ruutu T; Kröger N
Lancet Haematol; 2019 Feb; 6(2):e89-e99. PubMed ID: 30709437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]